CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Price, Quote, News and Overview
NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD
CMMB Quote, Performance and Key Statistics
1.28
-0.06 (-4.48%)
The current stock price of CMMB is 1.28 USD. In the past month the price increased by 17.43%. In the past year, price increased by 72.97%.
CMMB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.84 | 342.32B | ||
| AMGN | AMGEN INC | 14.56 | 155.14B | ||
| GILD | GILEAD SCIENCES INC | 13.46 | 129.91B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1736.21 | 129.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.47 | 62.19B | ||
| ARGX | ARGENX SE - ADR | 331.32 | 38.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.46B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.92B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| BIIB | BIOGEN INC | 7.3 | 17.59B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.42B |
Related stock screener links
About CMMB
Company Profile
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Company Info
CHEMOMAB THERAPEUTICS LTD
Kiryat Atidim, Building 7
TEL AVIV-YAFO 02139 IL
CEO: Neil Cohen
Employees: 16
Company Website: https://www.chemomab.com/
Investor Relations: https://investors.chemomab.com/
Phone: 972773310156
CHEMOMAB THERAPEUTICS LTD / CMMB FAQ
What is the stock price of CHEMOMAB THERAPEUTICS LTD today?
The current stock price of CMMB is 1.28 USD. The price decreased by -4.48% in the last trading session.
What is the ticker symbol for CHEMOMAB THERAPEUTICS LTD stock?
The exchange symbol of CHEMOMAB THERAPEUTICS LTD is CMMB and it is listed on the Nasdaq exchange.
On which exchange is CMMB stock listed?
CMMB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHEMOMAB THERAPEUTICS LTD stock?
9 analysts have analysed CMMB and the average price target is 9.18 USD. This implies a price increase of 617.19% is expected in the next year compared to the current price of 1.28. Check the CHEMOMAB THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHEMOMAB THERAPEUTICS LTD worth?
CHEMOMAB THERAPEUTICS LTD (CMMB) has a market capitalization of 24.14M USD. This makes CMMB a Nano Cap stock.
How many employees does CHEMOMAB THERAPEUTICS LTD have?
CHEMOMAB THERAPEUTICS LTD (CMMB) currently has 16 employees.
What are the support and resistance levels for CHEMOMAB THERAPEUTICS LTD (CMMB) stock?
CHEMOMAB THERAPEUTICS LTD (CMMB) has a support level at 1.08 and a resistance level at 1.31. Check the full technical report for a detailed analysis of CMMB support and resistance levels.
Should I buy CHEMOMAB THERAPEUTICS LTD (CMMB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CMMB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CMMB, evaluating the profitability, health, valuation and growth aspects
- CHEMOMAB THERAPEUTICS LTD (CMMB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHEMOMAB THERAPEUTICS LTD (CMMB) Sales and EPS estimates to see what analysts future expectations are.
- CHEMOMAB THERAPEUTICS LTD (CMMB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHEMOMAB THERAPEUTICS LTD (CMMB) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Chart to make your own analysis
- CHEMOMAB THERAPEUTICS LTD (CMMB) Latest news and press-releases to stay up to date.
Does CHEMOMAB THERAPEUTICS LTD (CMMB) stock pay dividends?
CMMB does not pay a dividend.
When does CHEMOMAB THERAPEUTICS LTD (CMMB) report earnings?
CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of CHEMOMAB THERAPEUTICS LTD (CMMB)?
CHEMOMAB THERAPEUTICS LTD (CMMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
What is the Short Interest ratio of CHEMOMAB THERAPEUTICS LTD (CMMB) stock?
The outstanding short interest for CHEMOMAB THERAPEUTICS LTD (CMMB) is 19.08% of its float. Check the ownership tab for more information on the CMMB short interest.
CMMB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CMMB. When comparing the yearly performance of all stocks, CMMB is one of the better performing stocks in the market, outperforming 90.22% of all stocks.
CMMB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CMMB. CMMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CMMB Financial Highlights
Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -0.56.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.9% | ||
| ROE | -88.24% | ||
| Debt/Equity | 0 |
CMMB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CMMB. The Buy consensus is the average rating of analysts ratings from 9 analysts.